DiscoverExpert Voices in DementiaStrategies to Limit ARIA Associated with Alzheimer Disease Treatment
Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Update: 2024-07-15
Share

Description

Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss new findings on baseline characteristics about amyloid-related imaging abnormalities (ARIA) in people with Alzheimer disease treated with donanemab.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Comments 
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
The BenfoTeam Clinical Trial: Investigating Benfotiamine as a Potential Therapy for Early Alzheimer Disease

The BenfoTeam Clinical Trial: Investigating Benfotiamine as a Potential Therapy for Early Alzheimer Disease

2024-11-1915:41

BrainCheck as a Digital Cognitive Assessment Tool

BrainCheck as a Digital Cognitive Assessment Tool

2024-11-0807:17

Kramer, Van Dyck

Kramer, Van Dyck

2024-09-2712:18

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 3

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 3

2024-09-2110:14

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 2

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 2

2024-09-2117:02

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 1

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 1

2024-09-2108:53

Labcorp's Biomarker Testing for Alzheimer Disease

Labcorp's Biomarker Testing for Alzheimer Disease

2024-09-1612:50

What Neurologists Should Know About End-of-Life Care Discussions

What Neurologists Should Know About End-of-Life Care Discussions

2024-07-1920:47

Insights into the Role of Tau in Alzheimer Disease and Neurodegenerative Disorders

Insights into the Role of Tau in Alzheimer Disease and Neurodegenerative Disorders

2024-07-1522:07

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

2024-07-1509:22

Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

2024-07-1508:51

Emerging Therapeutic Targets for Alzheimer Disease

Emerging Therapeutic Targets for Alzheimer Disease

2024-07-1514:27

Progress in Diagnosis and Management of Neuropsychiatric Symptoms in People Living with Dementia

Progress in Diagnosis and Management of Neuropsychiatric Symptoms in People Living with Dementia

2024-07-0713:05

How Healthcare Providers Can Partner with Caregivers of People Living with Dementia

How Healthcare Providers Can Partner with Caregivers of People Living with Dementia

2024-07-0718:10

Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Practical Neurology